Neurogene Inc. insider trading
Every open-market purchase and sale by Neurogene Inc.'s officers, directors and largest shareholders since November 4, 2021, and what the share price did next.
| Date | Insider | Trade | Shares | Price | Value | 1M after | 3M after | 6M after |
|---|
Does following Neurogene Inc.’s insiders pay?
From November 24, 2014 to November 27, 2024, 19 insiders reported 21 open-market purchases and 14 sales not made under a pre-set plan in Neurogene Inc. Twelve months after each purchase was reported, the shares were −26.1% against the S&P 500 on average (median −37.1%), over 18 purchases with a full year of prices; 22% beat the index. After sales, the shares moved −12.5% against the index over 12 months (a negative figure means selling was the right call). That rests on fewer than 20 purchases, too few to read much into. Buying each purchase the day after it was reported, an equal amount each, held 12 months or until that insider reported a sale, would have turned $10,000 on August 14, 2015 into $290 by November 2, 2026, −27.1% a year. It held shares 54% of the time; the S&P 500 on those same days, with Treasury bills otherwise, made $24,771 (+8.4% a year), and held throughout $43,434 (+14.0%).
| Insider | Role | Purchases | 12 months after their purchases | Beat the S&P 500 | Sales | 12 months after their sales | Latest report |
|---|---|---|---|---|---|---|---|
| Baker Felix | Director | 4 | +3.3% (3) | 33% | 0 | — | August 8, 2019 |
| Drachman Jonathan G | President and CEO | 4 | −63.9% (3) | 0% | 0 | — | August 26, 2021 |
| Johnson & Johnson | 10% owner | 0 | — | — | 4 | +35.1% (4) | August 12, 2015 |
| Baker Bros. Advisors LP | 10% owner | 3 | +20.5% (3) | 67% | 0 | — | January 9, 2017 |
| Johnson & Johnson Innovation - Jjdc, Inc. | 10% owner | 0 | — | — | 3 | +57.9% (3) | December 5, 2014 |
| Green Jeremy | 10% owner | 1 | −35.1% (1) | 0% | 1 | −35.1% (1) | April 6, 2020 |
| Mackenzie Lloyd | Chief Operating Officer | 0 | — | — | 2 | −74.2% (2) | March 19, 2018 |
| Mitchell David Chilton | VP Global Regulatory & Quality | 2 | −59.9% (2) | 0% | 0 | — | August 26, 2015 |
| 667, L.P. | Director | 1 | −24.5% (1) | 0% | 0 | — | December 20, 2019 |
| Akkaraju Srinivas | 10% owner | 1 | −35.8% (1) | 0% | 0 | — | November 27, 2024 |
| Alam Kamran | CFO, Vice President Finance | 0 | — | — | 1 | −60.7% (1) | August 14, 2015 |
| Baker Bros. Advisors (gp) LLC | 10% owner | 1 | +36.2% (1) | 100% | 0 | — | January 26, 2016 |
| Baker Brothers Life Sciences LP | Director | 1 | — | — | 0 | — | August 17, 2023 |
| Baker Julian | Director | 1 | −93.6% (1) | 0% | 0 | — | December 23, 2020 |
| Cvijic Christine Mikail | President and CFO | 1 | −38.4% (1) | 0% | 0 | — | November 25, 2024 |
| Ho Robert | Chief Financial Officer | 0 | — | — | 1 | −97.4% (1) | March 18, 2021 |
| Levitt Daniel J | Director | 0 | — | — | 1 | −85.9% (1) | May 16, 2018 |
| Mcminn Rachel | Chief Executive Officer | 1 | −38.4% (1) | 0% | 0 | — | November 25, 2024 |
| Pfizer Inc | 10% owner | 0 | — | — | 1 | −61.1% (1) | August 12, 2015 |
When several insiders traded Neurogene Inc.
Months when 2 or more insiders became net buyers, or 3 or more net sellers, of Neurogene Inc. in reports dated in the 91 days before the month end, and how the stock did against the S&P 500 from that month end. After the 3 buying crowds with six months of prices, it averaged −2.4% against the index. After 1 selling crowd, −47.5%. One company's history is too short to judge by; the test across every company is the better guide.
| Month | Crowd | 3 months on, vs S&P 500 | 6 months | 12 months |
|---|---|---|---|---|
| November 29, 2024 | 3 buying | −30.6% | −14.3% | −35.8% |
| December 31, 2019 | 2 buying | +10.7% | +40.6% | −1.5% |
| January 29, 2016 | 3 buying | −29.5% | −33.6% | +48.1% |
| August 31, 2015 | 4 selling | −36.0% | −47.5% | −50.3% |